Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | TTK | P33981 | 1/20 | 0.57 |
| ▸ | ULK1 | O75385 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561160 | 0.89 | LRRK2 (1.00) | LRRK2CYP1A2TTK | |
| SCHEMBL9275400 | 0.88 | LRRK2 (0.61) | LRRK2CYP1A2TTKULK1 | |
| SCHEMBL5021481 | 0.86 | LRRK2 (0.59) | LRRK2CYP1A2TTKULK1 | |
| SCHEMBL4530092 | 0.86 | LRRK2 (0.82) | LRRK2CYP1A2TTK | |
| SCHEMBL4538630 | 0.85 | LRRK2 (0.76) | LRRK2CYP1A2TTKULK1 | |
| SCHEMBL4530451 | 0.83 | LRRK2 (0.56) | LRRK2CYP1A2ULK1KITFLT3 | |
| SCHEMBL24146748 | 0.82 | LRRK2 (0.86) | LRRK2CYP1A2TTK | |
| SCHEMBL5021471 | 0.82 | LRRK2 (0.79) | LRRK2CYP1A2TTK | |
| SCHEMBL5021229 | 0.82 | LRRK2 (0.85) | LRRK2CYP1A2TTK | |
| SCHEMBL24146928 | 0.81 | LRRK2 (0.60) | LRRK2CYP1A2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | claimed |
| EP-3124483-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-07-10 | — | — | EP | claimed |
| EP-2638031-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3124483-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | claimed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-103313978-A | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | claimed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | disclosed |
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | disclosed |
| EP-3124483-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3124483-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-2638031-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2638031-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885CYP1A2 3177/4885TTK 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.